|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/25/22 bioAffinity Technologies, Inc. S-1/A 33:61M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-1/A Pre-Effective Amendment to Registration Statement HTML 1.47M
(General Form)
2: EX-1.1 Underwriting Agreement or Conflict Minerals Report HTML 176K
3: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 23K
4: EX-3.2 Articles of Incorporation/Organization or Bylaws HTML 18K
5: EX-3.3 Articles of Incorporation/Organization or Bylaws HTML 24K
6: EX-3.4 Articles of Incorporation/Organization or Bylaws HTML 13K
7: EX-3.5 Articles of Incorporation/Organization or Bylaws HTML 57K
8: EX-3.6 Articles of Incorporation/Organization or Bylaws HTML 91K
16: EX-4.10 Instrument Defining the Rights of Security Holders HTML 40K
17: EX-4.11 Instrument Defining the Rights of Security Holders HTML 33K
9: EX-4.2 Instrument Defining the Rights of Security Holders HTML 13K
10: EX-4.3 Instrument Defining the Rights of Security Holders HTML 41K
11: EX-4.4 Instrument Defining the Rights of Security Holders HTML 62K
12: EX-4.5 Instrument Defining the Rights of Security Holders HTML 80K
13: EX-4.6 Instrument Defining the Rights of Security Holders HTML 93K
14: EX-4.8 Instrument Defining the Rights of Security Holders HTML 130K
15: EX-4.9 Instrument Defining the Rights of Security Holders HTML 20K
18: EX-10.1 Material Contract HTML 74K
27: EX-10.10 Material Contract HTML 38K
19: EX-10.2 Material Contract HTML 16K
20: EX-10.3 Material Contract HTML 15K
21: EX-10.4 Material Contract HTML 16K
22: EX-10.5 Material Contract HTML 15K
23: EX-10.6 Material Contract HTML 16K
24: EX-10.7 Material Contract HTML 18K
25: EX-10.8 Material Contract HTML 24K
26: EX-10.9 Material Contract HTML 12K
28: EX-14.1 Code of Ethics HTML 20K
30: EX-21.1 Subsidiaries List HTML 11K
31: EX-23.2 Consent of Expert or Counsel HTML 12K
32: EX-23.3 Consent of Expert or Counsel HTML 11K
33: EX-FILING FEES Filing Fees HTML 35K
29: EX-16.1 Letter re: a Change in Accountant HTML 11K
EXHIBIT 4.9
Form of Secured Convertible Promissory Note
THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR UPON RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.
SECURED CONVERTIBLE PROMISSORY NOTE
| No. SCN-[NUMBER] | In San Antonio, Bexar County, Texas |
| $[PRINCIPAL AMOUNT] | Date of Issuance: [DATE] |
FOR VALUE RECEIVED, bioAffinity Technologies, Inc., a Delaware corporation located in San Antonio, Texas (the “Company”), hereby promises to pay to the order of [PURCHASER NAME] (the “Holder”), the principal sum of $[PRINCIPAL AMOUNT], together with simple interest thereon from the date of this Note. Interest will accrue at a rate of 8% per annum until this Note is converted in full or indefeasibly and irrevocably paid in full by the Company; provided, however, that immediately upon the occurrence and during the continuance of an Event of Default, interest will accrue interest at a rate equal to 13% per annum. Unless earlier converted into Conversion Shares pursuant to Section 4 of that certain Secured Convertible Note Purchase Agreement dated [DATE], by and among the Company, the Holder and the other parties thereto (the “Purchase Agreement”), the principal and accrued interest of this Note will be due and payable by the Company on the Maturity Date.
This Note is one of a series of Notes issued pursuant to the Purchase Agreement, and capitalized terms not defined herein will have the meanings set forth in the Purchase Agreement.
1. Payment; Prepayment. All payments will be made in lawful money of the United States of America at the principal office of the Company, or at such other place as the Holder may from time to time designate in writing to the Company. Payment will be credited first to accrued interest due and payable, with any remainder applied to principal. The Company will notify the Holder thirty (30) days prior to prepaying all or a portion of this Note to allow the Holder to exercise its right to an optional conversion as described in Section 4.2(b) of the Purchase Agreement. Subject to such notice requirement, the Company may, at any time, prepay all or any part of the unpaid principal amount of this Note without premium or penalty. Partial prepayments will be applied first to pay accrued unpaid interest and second, after all interest accrued through the date of such partial prepayment has been paid in full, to reduce the principal amount outstanding hereunder.
2. Security. This Note is a secured obligation of the Company, as secured by that certain Note Purchase Agreement dated as of [DATE].
3. Conversion of the Notes. This Note and any amounts due hereunder will be convertible into Conversion Shares in accordance with the terms of Section 4 of the Purchase Agreement.
4. Amendments and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any term of this Note, the resolution of any controversy or claim arising out of or relating to this Note and the provision of notice among the Company and the Holder will be governed by the terms of the Purchase Agreement.
C:
5. Successors and Assigns. This Note applies to, inures to the benefit of, and binds the respective successors and assigns of the parties hereto; provided, however, that the Company may not assign its obligations under this Note without the written consent of the Requisite Noteholders. Any transfer of this Note may be effected only pursuant to the Purchase Agreement and by surrender of this Note to the Company and reissuance of a new note to the transferee. The Holder and any subsequent holder of this Note receives this Note subject to the foregoing terms and conditions, and agrees to comply with the foregoing terms and conditions for the benefit of the Company and any other Purchasers (or their respective successors or assigns).
6. Officers and Directors not Liable. In no event will any officer or director of the Company be liable for any amounts due and payable pursuant to this Note.
7. Limitation on Interest. In no event will any interest charged, collected or reserved under this Note exceed the maximum rate then permitted by applicable law, and if any payment made by the Company under this Note exceeds such maximum rate, then such excess sum will be credited by the Holders as a payment of principal.
8. Choice of Law. This Note, and all matters arising out of or relating to this Note, whether sounding in contract, tort, or statute will be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to the conflict of laws provisions thereof to the extent such principles or rules would require or permit the application of the laws of any jurisdiction other than those of the State of Delaware.
9. Approval. The Company hereby represents that its board of directors, in the exercise of its fiduciary duty, has approved the Company’s execution of this Note based upon a reasonable belief that the principal provided hereunder is appropriate for the Company after reasonable inquiry concerning the Company’s financing objectives and financial situation. In addition, the Company hereby represents that it intends to use the principal of this Note primarily for the operations of its business, and not for any personal, family or household purpose.
C:
| BIOAFFINITY TECHNOLOGIES, INC. | ||
| By: | ||
| Maria Zannes | ||
| President and Chief Executive Officer | ||
C:
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/25/22 bioAffinity Technologies, Inc. S-1 6:5.2M M2 Compliance LLC/FA |